Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TUBB4A | P04350 | 11/20 | 0.46 |
| ▸ | TUBB | P07437 | 11/20 | 0.46 |
| ▸ | TUBA3C | P0DPH7 | 11/20 | 0.46 |
| ▸ | TUBA1B | P68363 | 11/20 | 0.46 |
| ▸ | TUBA4A | P68366 | 11/20 | 0.46 |
| ▸ | TUBB4B | P68371 | 11/20 | 0.46 |
| ▸ | TUBB3 | Q13509 | 11/20 | 0.46 |
| ▸ | TUBB2A | Q13885 | 11/20 | 0.46 |
| ▸ | TUBB8 | Q3ZCM7 | 11/20 | 0.46 |
| ▸ | TUBA3E | Q6PEY2 | 11/20 | 0.46 |
| ▸ | TUBA1A | Q71U36 | 11/20 | 0.46 |
| ▸ | TUBA1C | Q9BQE3 | 11/20 | 0.46 |
| ▸ | TUBB6 | Q9BUF5 | 11/20 | 0.46 |
| ▸ | TUBB2B | Q9BVA1 | 11/20 | 0.46 |
| ▸ | TUBB1 | Q9H4B7 | 11/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4469746 | 0.77 | DYRK1A (0.44) | SMN1; SMN2 | |
| SCHEMBL31400306 | 0.77 | POLB (0.45) | — | |
| SCHEMBL20839878 | 0.76 | KMT2A (0.45) | SMN1; SMN2 | |
| SCHEMBL13931951 | 0.76 | TUBB1 (0.53) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A | |
| SCHEMBL4474513 | 0.69 | DYRK1A (0.43) | SMN1; SMN2 | |
| SCHEMBL13931952 | 0.69 | TUBB4A (0.49) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A | |
| SCHEMBL4819729 | 0.68 | TUBB4A (0.75) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A | |
| SCHEMBL4479580 | 0.67 | CDK4 (0.43) | SMN1; SMN2 | |
| SCHEMBL4823325 | 0.67 | TUBB1 (0.59) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A | |
| SCHEMBL4799476 | 0.67 | TUBB1 (0.61) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7456289-B2 | Anti-tumor compounds | NATIONAL HEALTH RESEARCH INSTITUTES (TW) | 2008-11-25 | — | — | US | disclosed |
| US-7456289-B2 | Anti-tumor compounds | NATIONAL HEALTH RESEARCH INSTITUTES (TW) | 2008-11-25 | — | — | US | disclosed |
| US-7456289-B2 | Anti-tumor compounds | NATIONAL HEALTH RESEARCH INSTITUTES (TW) | 2008-11-25 | — | — | US | disclosed |
| US-7417035-B2 | Phospholipid derivatives of non-steroidal anti-inflammatory drugs | D-PHARM LTD. (IL) | 2008-08-26 | — | — | US | disclosed |
| EP-1838711-A2 | ANTI-TUMOR COMPOUNDS | National Health Research Institutes (TW) | 2007-10-03 | — | — | EP | disclosed |
| US-20070191310-A1 | Phospholipid derivatives of non-steroidal anti- inflammatory drugs | D-PHARM, LTD. (IL) | 2007-08-16 | — | — | US | disclosed |
| US-7173018-B2 | Phospholipid derivatives of non-steroidal anti-inflammatory drugs | D-PHARM, LTD. (IL) | 2007-02-06 | — | — | US | disclosed |
| WO-2006074041-A2 | ANTI-TUMOR COMPOUNDS | NATIONAL HEALTH RESEARCH INSTITUTES (TW) | 2006-07-13 | — | — | WO | disclosed |
| US-20060148801-A1 | Anti-tumor compounds | NATIONAL HEALTH RESEARCH INSTITUTES (TW) | 2006-07-06 | — | — | US | disclosed |
| US-20040209304-A1 | Methods of searching for solid forms and screening a sample according to its forms | PURDUE RESEARCH FOUNDATION | 2004-10-21 | — | — | US | disclosed |
| EP-0624087-B1 | SPRAY-CHILLED NABUMETONE | SMITHKLINE BEECHAM PLC (GB) | 1997-03-19 | — | — | EP | disclosed |
| US-5539000-A | Spray-chilled nabumetone | SMITHKLINE BEECHAM P.L.C. (GB) | 1996-07-23 | — | — | US | disclosed |
| EP-0624087-A1 | SPRAY-CHILLED NABUMETONE. | SMITHKLINE BEECHAM PLC (GB) | 1994-11-17 | — | — | EP | disclosed |
| WO-1993014747-A1 | SPRAY-CHILLED NABUMETONE | SMITHKLINE BEECHAM PLC (GB) | 1993-08-05 | — | — | WO | disclosed |
| EP-0322068-B1 | DERIVATIVES OF THIAZOLIDINE-4-CARBOXYLIC ACID HAVING PHARMACOLOGICAL ACTIVITY | ZAMBON GROUP S.p.A. (IT) | 1993-07-28 | — | — | EP | disclosed |
| US-4952596-A | Derivatives of thiazolidine-4-carboxylic acid having pharmacological activity | ZAMBON S.P.A. (IT) | 1990-08-28 | — | — | US | disclosed |
| EP-0322068-A1 | Derivatives of thiazolidine-4-carboxylic acid having pharmacological activity | ZAMBON GROUP S.p.A. (IT) | 1989-06-28 | — | — | EP | disclosed |
| US-4420639-A | Aromatic compounds | BEECHAM GROUP LIMITED (GB) | 1983-12-13 | — | — | US | disclosed |
| EP-0003643-A1 | Process for the preparation of 4-(6-methoxy-2-naphthyl)-butan-2-one; 4-(6-methoxy-2-naphthyl)-4-hydroxybut-3-en-2-one and a process for its preparation | BEECHAM GROUP PLC (GB) | 1979-08-22 | — | — | EP | disclosed |
| EP-0003643-A1 | Process for the preparation of 4-(6-methoxy-2-naphthyl)-butan-2-one; 4-(6-methoxy-2-naphthyl)-4-hydroxybut-3-en-2-one and a process for its preparation | BEECHAM GROUP PLC (GB) | 1979-08-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060148801-A1 | Anti-tumor compounds | TUBB1, TUBB3, TUBB | TUBB4A 5/4885TUBB 3/4885TUBA3C 18/4885 |
| US-20070191310-A1 | Phospholipid derivatives of non-steroidal anti- inflammatory drugs | PTGIS, PTGES, PHOSPHO1 | TUBB4A 1417/4885TUBB 1862/4885TUBA3C 2902/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.